↓ Skip to main content

PCSK9 and hypercholesterolemia: Therapeutical approach. - PubMed - NCBI

Overview of attention for article published in Current Drug Targets, December 2017
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
10 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
PCSK9 and hypercholesterolemia: Therapeutical approach. - PubMed - NCBI
Published in
Current Drug Targets, December 2017
DOI 10.2174/1389450119666171205101401
Pubmed ID
Authors

Obradovic, Milan, Zaric, Bozidarka, Sudar-Milovanovic, Emina, Ilincic, Branislava, Perovic, Milan, Stokic, Edita, Isenovic, Esma

Abstract

Despite the intensive research and progress in modern pharmacotherapy, hypercholesterolemia and related cardiovascular complications remain one of the leading causes of mortality and disability in the modern world. A significant contribution to the treatment of hypercholesterolemia was made by the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9). This enzyme is responsible for the degradation of the low-density lipoprotein (LDL) receptor (LDLR) found at the surface of the plasma membrane in the liver and directly associated with serum LDL level. Limitations in standard therapy used in the treatment of lipid disorders have led to the development of new drugs, such as an inhibitor of PCSK9. Over the past years, the greatest achievement in discovering the PCSK9 inhibitor was made by designing monoclonal antibodies that disable PCSK9 to bind LDLR and RNA interference to reduce PCSK9 production, but one of the main disadvantages is cost-effectiveness. In this review, we will summarize the most recent findings of basic and clinical studies which focus on PCSK9 function, regulation and therapeutic target for the treatment of hypercholesterolemia and associated cardiovascular diseases.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 10 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 3 30%
Student > Bachelor 2 20%
Student > Master 2 20%
Librarian 1 10%
Researcher 1 10%
Other 1 10%
Readers by discipline Count As %
Medicine and Dentistry 3 30%
Biochemistry, Genetics and Molecular Biology 2 20%
Psychology 1 10%
Social Sciences 1 10%
Pharmacology, Toxicology and Pharmaceutical Science 1 10%
Other 1 10%
Unknown 1 10%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 December 2017.
All research outputs
#10,870,572
of 12,265,937 outputs
Outputs from Current Drug Targets
#618
of 779 outputs
Outputs of similar age
#284,849
of 343,673 outputs
Outputs of similar age from Current Drug Targets
#12
of 17 outputs
Altmetric has tracked 12,265,937 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 779 research outputs from this source. They receive a mean Attention Score of 2.8. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 343,673 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.